Great science isn’t enough:

Author:

Andrew Moore, Client Engagement Director, Inizio Engage XD

The uncomfortable truth about symposia

Industry-sponsored symposia are widely regarded as a success. They attract large audiences, are taken seriously by healthcare professionals, and are often cited as one of the most valuable ways pharmaceutical companies contribute to medical education at congress.

That reputation, however, has become part of the problem.

Because symposia are seen as “working”, their format has remained largely unchanged, even as congress environments have become more competitive and HCP expectations have evolved. In today’s congested agendas, strong science alone no longer guarantees attention, engagement or impact.

Still valuable, but increasingly vulnerable

The IPCAA and Emota HCP Congress Experience research confirms that symposia continue to matter. Around two thirds of HCPs attend industry-sponsored symposia, and the vast majority rate their scientific quality as good or excellent.

More importantly, two out of three HCPs report that information received at industry-sponsored symposia has changed their clinical practice or prescribing behaviour. This reinforces symposia as one of the few industry engagements with clear downstream relevance to patient care.

But the same data reveals where value is being lost.

The single biggest barrier to attendance is not content quality. It is timing. Overcrowded congress schedules and overlapping sessions force HCPs to choose, and even high-quality symposia lose out. Evidence consistently shows that shorter formats, around 45 minutes, reduce scheduling friction and improve attendance without compromising educational value.

Length and format, not science, are now the limiting factors.

How HCPs want to learn has changed

HCPs are explicit about what makes symposia worth their time. Practical clinical application consistently ranks highest, followed by time for discussion, questions and interaction. Traditional, presentation-heavy sessions are far less effective at sustaining attention or driving learning.

Real-world patient case studies play a central role. They allow HCPs to test data against daily clinical realities, explore uncertainty, and hear how peers apply evidence in practice. These moments of applied discussion are where confidence, understanding and relevance are built.

Scientific credibility is equally critical. HCPs place the greatest value on balanced, objective presentation of data, independent moderation and multiple expert perspectives. Promotional tone actively detracts from perceived value. The strongest symposia prioritise education, dialogue and transparency over messaging.

Symposia as insight, not just exposure

When redesigned with interaction at their core, symposia do more than educate. They generate insight.

Live polling, audience Q&A, case-path selection and feedback tools surface knowledge gaps, clinical decision drivers, areas of hesitation and unmet needs. This intelligence goes far beyond attendance numbers and provides meaningful input for content planning, post-congress engagement and future investment decisions.

In this sense, modern symposia function as both an educational platform and a measurement engine, provided they are designed deliberately.

The risk of doing nothing

Symposia that fail to evolve do not fail dramatically. They fail quietly.

They become longer, less attended and less differentiated. Audiences disengage earlier, questions go unasked, insight goes uncaptured, and value is assumed rather than demonstrated. In a highly competitive congress environment, this represents a gradual erosion of both educational impact and return on investment.

What reimagined symposia look like

Treating symposia as high-value educational products, rather than one-off presentations, requires a shift in mindset. The most effective symposia are:

• Shorter, reducing scheduling friction and increasing attendance
• Interactive, with discussion and audience participation built in
• Case-led and clinically relevant, grounded in real-world practice
• Balanced and credible, prioritising education over promotion
• Measurable by design, generating insight as well as engagement

A strategic decision, not a creative tweak

Reimagined symposia drive deeper learning, support behaviour change and improve patient relevance, while also delivering clearer evidence of value for pharmaceutical companies.

In an environment where attention is limited and expectations are rising, updating symposium design is not a creative nice-to-have. It is a strategic decision about whether this high-value format continues to deliver on its promise.